Flavopiridol in Treating Patients With Recurrent Prostate Cancer

National Cancer Institute (NCI)40 enrolled

Overview

Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

OBJECTIVES: I. Evaluate the clinical effectiveness of flavopiridol in patients with metastatic androgen independent adenocarcinoma of the prostate. II. Assess the toxic effects of flavopiridol in this patient population. OUTLINE: Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation. Patients are followed every 3 months until death.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

alvocidibDRUG

Eligibility

Sex: MALE

Medical Language ↔ Plain English

PATIENT CHARACTERISTICS: * Performance Status: ECOG 0-2 * Life Expectancy: At least 3 months * WBC at least 3,000/mm3 * Absolute neutrophil count at least 1,200/mm3 * Platelet count at least 100,000/mm3 * Hemoglobin at least 8 g/dL * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 2.5 times normal * Creatinine no greater than 1.5 mg/dL * Prostate-specific antigen at least 10 ng/mL (if bone only disease) * No prior or concurrent maligancies within 5 years, except nonmelanoma skin cancer * No serious medical illness * No cord compression symptoms PRIOR CONCURRENT THERAPY: * No prior chemotherapy * No prior suramin therapy * Prior or concurrent use of luteinizing hormone-releasing hormone allowed (no other concurrent hormonal therapy) * No prior anti-androgen therapy within 4 weeks of study * At least 4 weeks since prior radiotherapy * No prior strontium therapy

Locations (4)

Beckman Research Institute, City of Hope

Duarte, California, United States

University of California Davis Cancer Center

Sacramento, California, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

University of Wisconsin Comprehensive Cancer Center

Madison, Wisconsin, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.